Skip to main content

Abbott launches new generation of Afinion test system

6/8/2018
Abbott announced the launch of its Afinion 2 analyzer in the United States. This marks the newest generation of the Afinion system, which builds on the company’s heritage in empowering patients with information about their health.

The Afinion 2 streamlines and simplifies the delivery of accurate measurements of hemoglobin A1C, or HbA1C, and albumin to creatinine ratio results at the point of care. The system also arms health care professionals with information to make quick and accurate medical decisions, which allows for more time to be dedicated to counseling patients in a single office visit, the company said.

“By delivering rapid HbA1C and ACR test results, the Afinion 2 analyzer does more than streamline care; its life-changing technology helps people living with diabetes get the most out of their healthcare visits,” Elizabeth Balthrop, divisional vice president of Cardiometabolic and Informatics at Abbott, said. “Within a single visit, patients can obtain real-time feedback and insights on their condition, have an informed discussion with their provider and leave with a defined care plan.”

Afinion 2’s platform also offers all-in-one connectivity to laboratory and hospital information systems, and a quieter experience for clinicians and patients. Health care professionals can also use the device in such out-patient settings as clinics, community health centers, hospitals and long-term care facilities.

“Bringing point-of-care HbA1C into my practice was a game changer in terms of helping my patients with diabetes live better and spend less time at my office,” Saleh Aldasouqi, chief of the division of endocrinology at Michigan State University, said. “With the Afinion analyzer, I have reliable HbA1C results in just three minutes, which allows me to actively manage their care at the time of the patient encounter.”
X
This ad will auto-close in 10 seconds